Resum
Idioma original | Anglès |
---|---|
Pàgines (de-a) | 1583-1596 |
Nombre de pàgines | 14 |
Revista | AIDS (London, England) |
Volum | 30 |
Número | 10 |
DOIs | |
Estat de la publicació | Publicada - de juny 2016 |
SDG de les Nacions Unides
Aquest resultat contribueix als següents objectius de desenvolupament sostenible.
Accés al document
Altres arxius i enllaços
Fingerprint
Navegar pels temes de recerca de 'Improvements over time in short-term mortality following myocardial infarction in HIV-positive individuals'. Junts formen un fingerprint únic.Com citar-ho
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: AIDS (London, England), Vol. 30, Núm. 10, 06.2016, pàg. 1583-1596.
Producció científica: Contribució a revista › Article › Recerca › Avaluat per experts
TY - JOUR
T1 - Improvements over time in short-term mortality following myocardial infarction in HIV-positive individuals
AU - Hatleberg, C.I.
AU - Ryom, L.
AU - El-Sadr, W.
AU - Smith, C.
AU - Weber, R.
AU - Reiss, P.
AU - Fontas, E.
AU - Dabis, F.
AU - Law, M.
AU - Monforte, A.D.
AU - De Wit, S.
AU - Mocroft, A.
AU - Phillips, A.
AU - Lundgren, J.D.
AU - Sabin, C.
AU - Torres, Ferran
N1 - Cited By :8 Export Date: 17 February 2022 CODEN: AIDSE Correspondence Address: Hatleberg, C.I.; CHIP, Blegdamsvej 9, Denmark; email: [email protected] References: Nguyen, H.L., Saczynski, J.S., Gore, J.M., Waring, M.E., Lessar, D., Yarzebski, J., Long-term trends in short-term outcomes in acute myocardial infarction (2011) Am J Med, 124, pp. 939-946; Ford, E.S., Ajani, U.A., Croft, J.B., Crithchley, J.A., Labarte, D.R., Kottke, T.E., Explaining the decrease in U.S. Deaths from coronary disease 1980-2000 (2007) N Engl J Med, 356, pp. 2388-2398; Mondy, K., Overton, E.T., Grubb, J., Tong, S., Seyfried, W., Powderly, W., Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population (2007) Clin Infect Dis, 44, pp. 726-734; Perelló, R., Calvo, M., Miró, O., Castan'eda, M., Saubí, N., Camón, S., Clinical presentation of acute coronary syndrome in HIV infected adults: A retrospective analysis of a prospectively collected cohort (2011) Eur J Intern Med, 22, pp. 485-488; Glass, T.R., Ungsedhapand, C., Wolbers, M., Weber, R., Vernazza, P.L., Rickenbach, M., Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: The Swiss HIV cohort study (2006) HIV Med, 7, pp. 404-410; Sabin, C., D'Arminio Monforte, A., Friis-Moller, N., Weber, R., El-Sadr, W.M., Reiss, P., Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction (2008) Clin Infect Dis, 46, pp. 1101-1110; Friis-Moller, N., Sabin, C., Weber, R., D'Arminio Monforte, A., El-Sadr, W.M., Reiss, P., Adverse events of anti-HIV drugs (dad) study group. Combination antiretroviral therapy and the risk of myocardial infarction (2003) N Engl J Med, 349, pp. 1993-2003; Obel, N., Thomsen, H.F., Kronborg, G., Larsen, C.S., Hildebrandt, P.R., Sorensen, H.T., Ischemic heart disease in HIV-infected and HIV-uninfected individuals: A population-based cohort study (2007) Clin Infect Dis, 44, pp. 1625-1631; Lang, S., Mary-Krause, M., Cotte, L., Gilquin, J., Partisani, M., Simon, A., Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: A case-control study nested within the French hospital database on HIV ANRS cohort CO4 (2010) Arch Intern Med, 170, pp. 1228-1238. , for the French Hospital database on HIV-ANRS CO4; Friis-Moller, N., Reiss, P., Sabin, C., Weber, R., D'Arminio Monforte, A., El-Sadr, W., Class of antiretroviral drugs and the risk of myocardial infarction (2007) N Engl J Med, 356, pp. 1723-1735; Sabin, C., Worm, S.W., Weber, R., Reiss, P., El-Sadr, W., Dabis, F., Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D: A: D study: A multicohort collaboration (2008) Lancet, 371, pp. 1417-1426; Worm, S.W., Sabin, C., Weber, R., Reiss, P., El-Sadr, W., Dabis, F., Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: The data collection on adverse events of anti-HIV drugs (D:A:D) study (2010) J Infect Dis, 201, pp. 318-330; Triant, V.A., Lee, H., Hadigan, C., Grinspoon, S.K., Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease (2007) J Clin Endocrinol Metab, 92, pp. 2506-2512; Mary-Krause, M., Cotte, L., Simon, A., Partisani, M., Costagliola, D., Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men (2003) AIDS, 17, pp. 2479-2486; Savès, M., Chêne, G., Ducimetière, P., Leport, C., Le Moal, G., Amouyel, P., Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population (2003) Clin Infect Dis, 37, pp. 292-298; Hsue, P.Y., Hunt, P.W., Sinclair, E., Bredt, B., Franklin, A., Killian, M., Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses (2006) AIDS, 20, pp. 2275-2283; Lang, S., Mary-Krause, M., Cotte, L., Gilquin, J., Partisani, M., Simon, A., Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population (2010) AIDS, 24, pp. 1221-1230; Boccara, F., Mary-Krause, M., Teiger, E., Lang, S., Lim, P., Wahbi, K., Acute coronary syndrome in human immunodeficiency virus-infected patients: Characteristics and 1 year prognosis (2011) Eur Heart J, 32, pp. 41-50; Klein, D.B., Leyden, W.A., Xu, L., Chao, C.R., Horberg, M.A., Towner, W.J., Declining relative risk for myocardial infarction among HIV-positive compared with HIV-negative individuals with access to care (2015) Clin Infect Dis, 60, pp. 1278-1280; Rasmussen, L.D., May, M.T., Kronborg, G., Larsen, C.S., Pedersen, C., Gerstoft, J., Obel, N., Time trends for risk of severe age-related diseases in individuals with and without HIV infection in Denmark: A nationwide population-based cohort study (2015) Lancet HIV, 2, pp. e288-e298; Pocock, S., Bueno, H., Licour, M., Medina, J., Zhang, L., Annemans, L., Predictors of one-year mortality at hospital discharge after acute coronary syndromes: A new risk score from the EPICOR (long-term follow up of antithrombotic management patterns in acute coronary syndrome patients) study (2015) Eur Hear J Acute Cardiovasc Care, 4, pp. 509-517; D'Ascenzo, F., Cerrato, E., Biondi-Zoccai, G., Moretti, C., Omedè, P., Sciuto, F., Acute coronary syndromes in human immunodeficiency virus patients: A meta-analysis investigating adverse event rates and the role of antiretroviral therapy (2012) Eur Heart J, 33, pp. 875-880; Carballo, D., Delhumeau, C., Carballo, S., Bähler, C., Radovanovic, D., Hirschel, B., Increased mortality after a first myocardial infarction in human immunodeficiency virus-infected patients; A nested cohort study (2015) AIDS Res Ther, 12, pp. 1-9; Tunstall-Pedoe, H., Kuulasmaa, K., Amouyel, P., Arveiler, D., Rajakangas, A.M., Pajak, A., Myocardial infarction and coronary deaths in the World Health Organization, MONICA project registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents (1994) Circulation, 90, pp. 583-612; Kowalska, J.D., Friis-Moller, N., Kirk, O., Bannister, W., Mocroft, A., Sabin, C., The Coding Causes of Death in HIV (CoDe) Project: Initial results and evaluation of methodology (2011) Epidemiology, 22, pp. 516-523; Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the national cholesterol education program (NCEP) Expert panel on de- tection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) (2001) JAMA, 285, pp. 2486-2497; Yeh, R.W., Sidney, S., Chandra, M., Sorel, M., Selby, J.V., Go, A.S., Population trends in the incidence and outcomes of acute myocardial infarction (2010) N Engl J Med, 362, pp. 2155-2165; Hsue, P.Y., Giri, K., Erickson, S., MacGregor, J.S., Younes, N., Shergill, A., Clinical features of acute coronary syndromes in patients with human immunodeficiency virus infection (2004) Circulation, 109, pp. 316-319; Gazzaruso, C., Bruno, R., Garzaniti, A., Giordanetti, S., Fratino, P., Sacchi, P., Hypertension among HIV patients: Prevalence and relationships to insulin resistance and metabolic syndrome (2003) J Hypertens, 21, pp. 1377-1382; B'Kken, M., Os, I., Sandvik, L., Oektedalen, O., Hypertension in an urban HIV-positive population compared with the general population: Influence of combination antiretroviral therapy (2008) J Hypertens, 26, pp. 2126-2133; Calvo-Sánchez, M., Perelló, R., Pérez, I., Mateo, M., Junyent, M., Laguno, M., Differences between HIV-infected and uninfected adults in the contributions of smoking, diabetes and hypertension to acute coronary syndrome: Two parallel casecontrol studies (2013) HIV Med, 14, pp. 40-48; Smith, C.J., Ryom, L., Weber, R., Morlat, P., Pradier, C., Reiss, P., Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): A multicohort collaboration (2014) Lancet, 384, pp. 241-248; Causes of death in HIV-1-infected patients treated with antiretroviral therapy 1996-2006: Collaborative analysis of 13 HIV cohort studies (2010) Clin Infect Dis, 50, pp. 1387-1396. , Antiretroviral therapy Cohort Collaboration; Lewden, C., May, T., Rosenthal, E., Burty, C., Bonnet, F., Costagliola, D., Changes in causes of death among adults infected by HIV between 2000 and 2005: The "mortalité 2000 and 2005" surveys (ANRS EN19 and mortavic) (2008) J Acquir Immune Defic Syndr, 48, pp. 590-598; Ambrose, J.A., Gould, R.B., Kurian, D.C., DeVoe, M.C., Pearlstein, N.B., Coppola, J.T., Frequency of and outcome of acute coronary syndromes in patients with human immunodeficiency virus infection (2003) Am J Cardiol, 92, pp. 301-303; Matetzky, S., Domingo, M., Kar, S., Noc, M., Shah, P.K., Kaul, S., Acute myocardial infarction in human immunodeficiency virus-infected patients (2003) Arch Intern Med, 163, pp. 457-460; Varriale, P., Saravi, G., Hernandez, E., Carbon, F., Acute myocardial infarction in patients infected with human immunodeficiency virus (2004) Am Heart J, 147, pp. 55-59; Chaudhry, S.I., Khan, R.F., Chen, J., Dharmarajan, K., Dodson, J.A., Masoudi, F.A., National trends in recurrent ami hospitalizations 1 year after acute myocardial infarction in medicare beneficiaries 1999-2010 (2014) J Am Heart Assoc, 3, p. e001197; Rosengren, A., Wallentin, L., Gitt, A.K., Behar, S., Battler, A., Hasdai, D., Sex, age, and clinical presentation of acute coronary syndromes (2004) Eur Heart J, 25, pp. 663-670; Lorgis, L., Cottenet, J., Molins, G., Benzenine, E., Zeller, M., Aube, H., Outcomes after acute myocardial infarction in HIVinfected patients: Analysis of data from a French nationwide hospital medical information database (2013) Circulation, 127, pp. 1767-1774; Grunfeld, C., Dyslipidemia and its treatment in HIV infection (2010) Top HIV Med, 18, pp. 112-118; Canto, J.G., Kiefe, C.I., Rogers, W.J., Peterson, E.D., Frederick, P.D., French, W.J., Number of coronary heart disease risk factors and mortality in patients with first myocardial infarction (2011) JAMA, 306, pp. 2120-2127. , For the NRMI Investigators
PY - 2016/6
Y1 - 2016/6
N2 - Objective: Few studies have described mortality and clinical outcomes after myocardial infarction (MI) in the HIV-positive population. This study evaluated changes in short-term mortality after MI in HIV-positive individuals in the D:A:D Study, and investigated possible reasons for any changes seen. Design: Prospective cohort study. Methods: Demographic, cardiovascular disease (CVD)/HIV-related characteristics and CVD-related interventions (invasive cardiovascular procedures and drug interventions) were summarized at the time of and following an MI. Associations between calendar year and mortality in the first month after MI were identified using logistic regression with adjustment for confounders, including interventions received in the first month after MI. Results: One thousand and eight HIV-positive individuals experiencing an MI over the period 1999-2014 were included. The absolute number of MIs decreased from 214 (1999-2002) to 154 (2011-2014). Whilst the CVD risk profile remained high over time, the HIV status improved. The use of CVD-related interventions after MI appeared to increase over time. The proportion of individuals who died in the first month after MI dropped from 26.6% in 1999-2002 to 8.4% in 2011-2014. Later calendar year was associated with decreased short-term mortality; this effect was attenuated after adjusting for CVD-related interventions received in the first month after MI [odds ratio changed from 0.88 (95% confidence interval 0.83, 0.93) to 0.97 (0.91, 1.02)]. Conclusion: Improvements in short-term survival after MI appear to be largely driven by improved medical management of CVD risk in HIV-positive individuals after MI. Efforts are still needed to treat CVD risk factors and increase access to CVD-related interventions. Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.
AB - Objective: Few studies have described mortality and clinical outcomes after myocardial infarction (MI) in the HIV-positive population. This study evaluated changes in short-term mortality after MI in HIV-positive individuals in the D:A:D Study, and investigated possible reasons for any changes seen. Design: Prospective cohort study. Methods: Demographic, cardiovascular disease (CVD)/HIV-related characteristics and CVD-related interventions (invasive cardiovascular procedures and drug interventions) were summarized at the time of and following an MI. Associations between calendar year and mortality in the first month after MI were identified using logistic regression with adjustment for confounders, including interventions received in the first month after MI. Results: One thousand and eight HIV-positive individuals experiencing an MI over the period 1999-2014 were included. The absolute number of MIs decreased from 214 (1999-2002) to 154 (2011-2014). Whilst the CVD risk profile remained high over time, the HIV status improved. The use of CVD-related interventions after MI appeared to increase over time. The proportion of individuals who died in the first month after MI dropped from 26.6% in 1999-2002 to 8.4% in 2011-2014. Later calendar year was associated with decreased short-term mortality; this effect was attenuated after adjusting for CVD-related interventions received in the first month after MI [odds ratio changed from 0.88 (95% confidence interval 0.83, 0.93) to 0.97 (0.91, 1.02)]. Conclusion: Improvements in short-term survival after MI appear to be largely driven by improved medical management of CVD risk in HIV-positive individuals after MI. Efforts are still needed to treat CVD risk factors and increase access to CVD-related interventions. Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.
KW - cardiovascular disease
KW - cardiovascular interventions
KW - HIV infection
KW - mortality
KW - myocardial infarction
KW - antiretrovirus agent
KW - adult
KW - African
KW - antiretroviral therapy
KW - antiviral therapy
KW - Article
KW - cardiovascular mortality
KW - cardiovascular procedure
KW - cardiovascular risk
KW - CD4 lymphocyte count
KW - cerebrovascular accident
KW - dyslipidemia
KW - family history
KW - female
KW - follow up
KW - heart infarction
KW - high risk patient
KW - human
KW - Human immunodeficiency virus infected patient
KW - Human immunodeficiency virus infection
KW - hypertension
KW - intravenous drug abuse
KW - major clinical study
KW - male
KW - middle aged
KW - mortality rate
KW - outcome assessment
KW - priority journal
KW - short term survival
KW - smoking
KW - smoking cessation
KW - virus load
KW - complication
KW - disease management
KW - incidence
KW - prospective study
KW - survival analysis
KW - Adult
KW - Disease Management
KW - Female
KW - HIV Infections
KW - Humans
KW - Incidence
KW - Male
KW - Middle Aged
KW - Myocardial Infarction
KW - Prospective Studies
KW - Survival Analysis
UR - http://www.ncbi.nlm.nih.gov/pubmed/26950315
U2 - 10.1097/QAD.0000000000001076
DO - 10.1097/QAD.0000000000001076
M3 - Article
C2 - 26950315
SN - 0269-9370
VL - 30
SP - 1583
EP - 1596
JO - AIDS (London, England)
JF - AIDS (London, England)
IS - 10
ER -